基础医学与临床 ›› 2023, Vol. 43 ›› Issue (2): 322-326.doi: 10.16352/j.issn.1001-6325.2023.02.322

• 短篇综述 • 上一篇    下一篇

NLRP3炎性小体在高尿酸血症肾病中作用的研究进展

代志新1*, 王玉敏2   

  1. 1.赤峰学院附属医院 全科医疗科, 内蒙古 赤峰 024005;
    2.航天中心医院/北京大学航天临床医学院 呼吸与危重症医学科, 北京 100049
  • 收稿日期:2021-11-03 修回日期:2022-04-12 出版日期:2023-02-05 发布日期:2023-02-02
  • 通讯作者: *1370572086@qq.com
  • 基金资助:
    内蒙古自然科学基金(2020MS08175,2021MS08131,2021LHMS08024); 内蒙古自治区高校科研项目(NJZY19218);航天中心医院院级课题(YN202104)

Progress on the role of NLRP3 inflammasome in hyperuricemic nephropathy

DAI Zhixin1*, WANG Yumin2   

  1. 1. Department of General Family Medicine, the Affiliated Hospital of Chifeng University, Chifeng 024005;
    2. Department of Respiratory and Critical Care Medicine,Aerospace Center Hospital,Peking University Aerospace School of Clinical Medicine, Beijing 100049, China
  • Received:2021-11-03 Revised:2022-04-12 Online:2023-02-05 Published:2023-02-02
  • Contact: *1370572086@qq.com

摘要: 高尿酸血症肾病(HN)是高尿酸血症(HU)常见的临床并发症,可导致HU相关的肾脏异常。本文阐述与HN相关机制,强调了核苷酸结合寡聚化结构域样受体蛋白3(NLRP3)炎性小体激活在HN发生和发展中的作用,指出药物靶向抑制NLRP3炎性小体激活是HN的治疗靶点。

关键词: 高尿酸血症肾病, 高尿酸血症, NLRP3炎性小体, 抑制剂

Abstract: Hyperuricemic nephropathy (HN) is a common clinical complication of hyperuricemia, leading to hyperuricemia-associated renal abnormalities. The present review sheds light on the mechanistic aspects pertaining to HN, emphasizing the role of nucleotide-binding oligomerization domain leucine-rich repeat and pyrin domain-containing protein 3 (NLRP3) inflammasome activation in the occurrence and development of HN.This review recommends pharmacological inhibition of NLRP3 infammasome as a therapeutic strategy of HN treatment.

Key words: hyperuricemic nephropathy, hyperuricemia, NLRP3 inflammasome, inhibitor

中图分类号: